The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $2,424,067 project grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for the "DEVELOPMENT OF ANTI-DYT1 DYSTONIA GENE EDITING THERAPIES". The grant, with a performance period from Jul 1, 2024 to Jun 30, 2028, will support MGH's research to develop new gene editing therapies for treating DYT1 dystonia, a rare neurological disorder. As a leading academic medical center, MGH will leverage its specialized expertise and facilities to conduct foundational biomedical research, including clinical trials and laboratory studies, aimed at advancing the understanding and treatment of DYT1 dystonia. This project grant is part of the Military Medical Research and Development program's broader efforts to fund innovative, high-impact research to improve the health and care of military service members, veterans, and their families.
Generated 12/10/24, 8:26 AM